Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection

Kwok Hung Lai, Yang Te Tsai, Shou Dong Lee, Wai Wah Ng, Ho Chung Teng, Tseng Nip Tam, Gin Ho Lo, Han Chieh Lin, Hwai Jeng Lin, Jaw Ching Wu, Chii Shyan Lay, Sun Sang Wang, Wing Kai Chan

研究成果: 雜誌貢獻文章同行評審

26 引文 斯高帕斯(Scopus)

摘要

A total of 20 patients with histologically proven primary hepatocellular carcinoma (PHC) received mitoxantrone IV at a dose of 10-16 mg/m2 every 3 weeks. All patients had previous hepatitis B infection. None underwent remission after treatment; 2 had stable disease and 18 progressive disease. The median overall survival was 13 weeks (range, 1-59 weeks). There was no evidence of significant antitumor activity for mitoxantrone in our patients with PHC. Hematotoxicity occurred in 100% of the patients with grades 2-4 leukopenia, 89% of those with grades 1-4 anemia, and 26% of those with grades 2-3 thrombocytopenia. Cardiotoxicity occurred in 20% of the patients after 14-30 mg/m2 mitoxantrone; these included complete heart block with fatal outcome in one case, decreased ventricular ejection fraction in one, and sinus tachycardia in two. Nausea, vomiting, fever, diarrhea, and alopecia were mild and occurred in 15%-45% of the patients (Table 3). Therefore, patients with PHC following hepatitis B infection may be less tolerant to mitoxantrone, resulting in the apparent increase in toxicities.

原文英語
頁(從 - 到)54-56
頁數3
期刊Cancer Chemotherapy and Pharmacology
23
發行號1
DOIs
出版狀態已發佈 - 一月 1989
對外發佈Yes

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

指紋 深入研究「Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection」主題。共同形成了獨特的指紋。

引用此